1
|
Qu X, Zhai Z, Liu X, et al: Dioscin
inhibits osteoclast differentiation and bone resorption through
down-regulating the Akt signaling cascades. Biochem Biophys Res
Commun. 443:658–665. 2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Lieben L, Carmeliet G and Masuyama R:
Calcemic actions of vitamin D: Effects on the intestine, kidney and
bone. Best Pract Res Clin Endocrinol Metab. 25:561–572. 2011.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Lieben L and Carmeliet G: Vitamin D
signaling in osteocytes: Effects on bone and mineral homeostasis.
Bone. 54:237–243. 2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Kogawa M, Anderson PH, Findlay DM, et al:
The metabolism of 25-(OH)vitamin D3 by osteoclasts and their
precursors regulates the differentiation of osteoclasts. J Steroid
Biochem Mol Biol. 121:277–280. 2010. View Article : Google Scholar : PubMed/NCBI
|
5
|
Uchiyama Y, Higuchi Y, Takeda S, et al:
ED-71, a vitamin D analog, is a more potent inhibitor of bone
resorption than alfacalcidol in an estrogen-deficient rat model of
osteoporosis. Bone. 30:582–588. 2002. View Article : Google Scholar : PubMed/NCBI
|
6
|
Song R, Gu J, Liu X, Zhu J, Wang Q, Gao Q,
Zhang J, Cheng L, Tong X, Qi X, et al: Inhibition of osteoclast
bone resorption activity through osteoprotegerin-induced damage of
the sealing zone. Int J Mol Med. 34:856–862. 2014.PubMed/NCBI
|
7
|
Gu JH, Tong XS, Chen GH, et al: Regulation
of matrix metalloproteinase-9 protein expression by
1α,25-(OH)2D3 during osteoclast
differentiation. J Vet Sci. 15:133–140. 2014. View Article : Google Scholar : PubMed/NCBI
|
8
|
Teitelbaum SL: Osteoclasts: What do they
do and how do they do it? Am J Pathol. 170:427–435. 2007.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Brinkmann J, Hefti T, Schlottig F, et al:
Response of osteoclasts to titanium surfaces with increasing
surface roughness: An in vitro study. Biointerphases.
7:342012. View Article : Google Scholar : PubMed/NCBI
|
10
|
Suda T, Takahashi F and Takahashi N: Bone
effects of vitamin D - Discrepancies between in vivo and
in vitro studies. Arch Biochem Biophys. 523:22–29. 2012.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Takasu H, Sugita A, Uchiyama Y, et al:
c-Fos protein as a target of anti-osteoclastogenic action of
vitamin D and synthesis of new analogs. J Clin Invest. 116:528–535.
2006. View
Article : Google Scholar : PubMed/NCBI
|
12
|
Zhu K, Gläser R and Mrowietz U: Vitamin
D(3) and analogues modulate the expression of CSF-1 and its
receptor in human dendritic cells. Biochem Biophys Res Commun.
297:1211–1217. 2002. View Article : Google Scholar : PubMed/NCBI
|
13
|
Medhora MM, Teitelbaum S, Chappel J, et
al: 1 alpha, 25-dihydroxyvitamin D3 up-regulates expression of the
osteoclast integrin alpha v beta 3. J Biol Chem. 268:1456–1461.
1993.PubMed/NCBI
|
14
|
Takahashi N, Yamana H, Yoshiki S, et al:
Osteoclast-like cell formation and its regulation by osteotropic
hormones in mouse bone marrow cultures. Endocrinology.
122:1373–1382. 1988. View Article : Google Scholar : PubMed/NCBI
|
15
|
DeLuca HF: History of the discovery of
vitamin D and its active metabolites. Bonekey Rep. 3:4792014.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Arai F, Miyamoto T, Ohneda O, et al:
Commitment and differentiation of osteoclast precursor cells by the
sequential expression of c-Fms and receptor activator of nuclear
factor κB (RANK) receptors. J Exp Med. 190:1741–1754. 1999.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Price CP, Kirwan A and Vader C:
Tartrate-resistant acid phosphatase as a marker of bone resorption.
Clin Chem. 41:641–643. 1995.PubMed/NCBI
|
18
|
Kim TH, Lee B, Kwon E, et al:
1,25-Dihydroxyvitamin D3 inhibits directly human osteoclastogenesis
by down-regulation of the c-Fms and RANK expression. Joint Bone
Spine. 80:307–314. 2013. View Article : Google Scholar : PubMed/NCBI
|
19
|
Väänänen HK, Liu YK, Lehenkari P and
Uemara T: How do osteoclasts resorb bone? Mater Sci Eng C.
6:205–209. 1998. View Article : Google Scholar
|
20
|
Grüneberg S, Stubbs MT and Klebe G:
Successful virtual screening for novel inhibitors of human carbonic
anhydrase: Strategy and experimental confirmation. J Med Chem.
45:3588–3602. 2002. View Article : Google Scholar : PubMed/NCBI
|
21
|
Väänänen K: Mechanism of osteoclast
mediated bone resorption - rationale for the design of new
therapeutics. Adv Drug Deliv Rev. 57:959–971. 2005. View Article : Google Scholar : PubMed/NCBI
|
22
|
Xie L, Moroi Y, Hayashida S, et al:
Cathepsin K-upregulation in fibroblasts promotes matrigel invasive
ability of squamous cell carcinoma cells via tumor-derived IL-1α. J
Dermatol Sci. 61:45–50. 2011. View Article : Google Scholar : PubMed/NCBI
|
23
|
Ishibashi O, Niwa S, Kadoyama K and Inui
T: MMP-9 antisense oligodeoxynucleotide exerts an inhibitory effect
on osteoclastic bone resorption by suppressing cell migration. Life
Sci. 79:1657–1660. 2006. View Article : Google Scholar : PubMed/NCBI
|